While most pharma companies have exited the ... These will slot into Shionogi’s portfolio alongside Fetroja (cefiderocol), billed as the first and only siderophore cephalosporin antibiotic ...

Founded in 1878 and based in Osaka, Japan, Shionogi is a drug-discovery-based pharmaceutical company with more than 5,500 employees and operations around the globe, including offices in the US ...

Shionogi is a global pharmaceutical company established more than 140 years ago in Osaka, Japan. Shionogi is committed to prioritising patients and the company recognises the importance of ...

The oral drug Xocova marks the first home-grown medication, developed by Shionogi & Co ... The system allows pharmaceutical companies to apply for emergency approval based on the results of ...

Iwasaki attributed the decision to shifts in business strategies and emphasized that Shionogi will focus on new drug launches in China, including Phase 3-completed Cefiderocol and Naldemedine.

Drug developer Maze Therapeutics eyes up to $728 million valuation in US IPO January 27, 2025 Japan's Shionogi & Co said ... a move that will require the pharmaceutical companies to pay Medicare ...

As a discovery-based pharmaceutical company, Shionogi is focused on researching and developing more effective medications and pharmaceuticals to protect the health and well-being of patients.